Importantly, in vitro experiments using CFTR expressing lung adenocarcinoma cells showed that exposure to therapeutic levels of the CFTR potentiator ivacaftor, clinically approved for the treatment of cystic fibrosis, significantly reduced proliferation and showed additive effects with anthracyclines. This evidence concerns the gene CFTR and lung adenocarcinoma.